Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | CDC7 | O00311 | 1/20 | 0.61 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.61 |
| ▸ | CDK2 | P24941 | 1/20 | 0.61 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | RORB | Q92753 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | BTK | Q06187 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1246354 | 0.91 | ALDH1A1 (0.58) | ALDH1A1HSD17B10CDC7CCNE1CDK2 | |
| SCHEMBL2762916 | 0.88 | ALDH1A1 (0.64) | ALDH1A1HSD17B10CDC7CCNE1CDK2 | |
| SCHEMBL27653923 | 0.88 | ALDH1A1 (0.64) | ALDH1A1HSD17B10CYP1A2MAPTCYP2D6 | |
| Hydrochloric Acid SCHEMBL27583076 | 0.86 | ALDH1A1 (0.62) | ALDH1A1HSD17B10CDC7CCNE1CDK2 | |
| SCHEMBL27583074 | 0.85 | ALDH1A1 (0.61) | ALDH1A1HSD17B10CDC7CCNE1CDK2 | |
| SCHEMBL330400 | 0.85 | ALDH1A1 (0.65) | ALDH1A1HSD17B10CYP1A2MAPTCYP2D6 | |
| SCHEMBL2491634 | 0.83 | POLB (0.55) | ALDH1A1HSD17B10CDC7CCNE1CDK2 | |
| SCHEMBL165773 | 0.83 | ADORA3 (0.61) | ALDH1A1HSD17B10CYP1A2MAPTCYP2D6 | |
| SCHEMBL4740819 | 0.83 | CDC7 (0.85) | ALDH1A1CDC7CCNE1CDK2DBF4 | |
| SCHEMBL956697 | 0.83 | CDC7 (0.61) | ALDH1A1HSD17B10CDC7CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379543-A2 | THIAZOLYL-BENZIMIDAZOLES | F. Hoffmann-La Roche AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| US-8044213-B2 | Thiazolyl-benzimidazoles | HOFFMANN-LA ROCHE INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044213-B2 | Thiazolyl-benzimidazoles | HOFFMANN-LA ROCHE INC. (US) | 2011-10-25 | — | — | US | disclosed |
| WO-2010121675-A2 | THIAZOLYL-BENZIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100160308-A1 | Thiazolyl-Benzimidazoles | CAI JIANPING | 2010-06-24 | — | — | US | disclosed |
| US-20100160308-A1 | Thiazolyl-Benzimidazoles | CAI JIANPING | 2010-06-24 | — | — | US | disclosed |
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | REMPEX PHARMACEUTICALS, INC. | 2008-03-27 | — | — | US | disclosed |
| EP-1758920-A1 | BACTERIAL EFFLUX PUMP INHIBITORS AND METHODS OF TREATING BACTERIAL INFECTIONS | MPEX PHARMACEUTICALS, INC. (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20060003944-A1 | Bacterial efflux pump inhibitors and methods of treating bacterial infections | REMPEX PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
| WO-2005113579-A1 | BACTERIAL EFFLUX PUMP INHIBITORS AND METHODS OF TREATING BACTERIAL INFECTIONS | MPEX PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| US-4006127-A | Cationic diazacyanine dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | ABCB1, ABCB11, SLC47A2 | ALDH1A1 3712/4885HSD17B10 2763/4885CDC7 3848/4885 |
| US-20060003944-A1 | Bacterial efflux pump inhibitors and methods of treating bacterial infections | ABCB11, ABCB1, ABCC1 | ALDH1A1 2512/4885HSD17B10 1168/4885CDC7 3859/4885 |
| US-20100160308-A1 | Thiazolyl-Benzimidazoles | CYP3A7, CYP2C19, CYP3A5 | ALDH1A1 100/4885HSD17B10 683/4885CDC7 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.